Additive hypoglycaemic effect of nateglinide and exogenous glucagon-like peptide-1 in type 2 diabetes.
Author(s): Bell PM, Cuthbertson J, Patterson S, O'Harte FP
Affiliation(s): Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, UK. patrick.bell@belfasttrust.hscni.net
Publication date & source: 2011-03, Diabetes Res Clin Pract., 91(3):e68-70. Epub 2010 Dec 30.
Publication type: Clinical Trial; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
We examined the postprandial glucose regulators nateglinide and GLP-1, separately and in combination, in people with type 2 diabetes. Nateglinide inhibited DPP-4 activity, reduced GLP-1 degradation and enhanced its insulinotropic and blood glucose lowering effect. Combining nateglinide and GLP-1 derivatives may effectively control postprandial glycaemia. Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
|